Navigation Links
Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference
Date:7/20/2011

ses. 250 patients have received CMX001 under Emergency Investigational New Drug Applications (EINDs), including for treatment of orthopox viruses. A significant number of the individuals receiving CMX001 in human testing have been immunocompromised as a result of disease or immunosuppressing therapies associated with stem cell or solid organ transplantation.

Clinical studies of CMX001 include an ongoing Phase 2 study for the prevention/control of cytomegalovirus (a herpes virus) in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV HALT Trial/CMX001-202); and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections. The open-label study builds on Chimerix's extensive experience working with over 150 clinicians at over 80 leading institutions in the United States, Canada, Europe, and Israel who have sought CMX001 under EINDs for the treatment of immunocompromised patients.

CMX001 and Smallpox Antiviral Development

CMX001 is a leading antiviral candidate as a medical countermeasure against a smallpox release, including the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine. Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient car
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Appoints Timothy W. Trost Senior Vice President, Chief Financial Officer
2. Chimerix to Present at Cowen and Company 31st Annual Health Care Conference
3. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
4. Chimerix to Present at the Citi 2011 Global Health Care Conference
5. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
6. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
7. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at 9th Annual BIO Investor Forum
10. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
11. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Critical Process Filtration, ... , today announces the expansion of their Technical ... Process Filtration now offers customers and potential customers ... to filter failure analyses (even for competitor filters) ... their hallmark services of system benchmarking and cost/performance ...
(Date:8/28/2014)... -- Rx Safes, Inc., the manufacturer of fingerprint recognition home ... new war on drugs to reduce prescription drug abuse, ... than 2,500 children a day experiment with prescription drugs ... accessed from unsecured medicine cabinets, closets and drawers.  While law ... Safes will address the new age drug dealer in ...
(Date:8/28/2014)... , Californie, 28 août 2014 ... annoncé aujourd,hui le début des inclusions ... étude  d,exemption des dispositifs expérimentaux (ou ... à évaluer l,innocuité et l,efficacité du ... Le docteur Adam Arthur , ...
Breaking Medicine Technology:Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2Rx Safes, Inc. Announces New War On Drugs 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
... 1, 2011 Hologic, Inc. (Hologic or ... developer, manufacturer and supplier of premium diagnostics, medical imaging ... needs of women, today announced it has acquired TCT ... in China, including Hologic,s ThinPrep Pap Test, related instruments ...
... Technology makes the PROFIT 200 list for the third ... Technology, headquartered in Toronto, has been included in the ... by PROFIT Magazine. Ranking Canada,s Fastest-Growing Companies by five-year ... successful growth companies. Published in the Summer issue of ...
Cached Medicine Technology:Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 2Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 3Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 4Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 5Claron Technology Makes the PROFIT 200 List for the Third Consecutive Year 2
(Date:8/28/2014)... Commercial growers all over the continent are waitlisted ... grow lights, which perform on par with 1000w HPS at ... lighting needs no cooling equipment and does not overheat the ... Factoring in that they never need bulbs changed, the internal ... year. , For many indoor growers, cooler room temperatures also ...
(Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
(Date:8/28/2014)... place glue directly on the nerve stumps, but this ... allows glue to easily invade the nerve ends. Ordinarily, ... insert the nerve ends into the conduit because the ... Liang and co-workers from the General Hospital of Chinese ... and defined the best parameters for its use through ...
(Date:8/28/2014)... of patients with stage III colon cancer had improved ... a new study in Gastroenterology ... Association. , When added to the standard chemotherapy treatment ... overall survival rates for patients with the CpG island ... to 20 percent of colorectal cancers. Patients with CIMP-negative ...
(Date:8/28/2014)... in the study who were on a class of ... as prescribed in the first six months. Patients from ... around the UK involved in the study. , Researchers ... Genomics at The University of Manchester, who led the ... known as ,non-adherence, reduced their effectiveness and may lead ...
Breaking Medicine News(10 mins):Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Drug shows promise for subset of stage III colon cancer patients 2Health News:Arthritis patients failing to take expensive medication, according to new research 2
... substantially reduce the risk of ovarian cancer in women ... research. Researchers say the magnitude of the risk reduction ... cancer has the highest fatality rate of all gynecological ... the strong predictors of developing ovarian cancer is a ...
... said on Thursday they were combining two new and experimental ... try to treat muscular dystrophy. Their early work has shown ... is years away. ,Writing in the journal Science, the ... Research Institute in Milan and the University of Rome said ...
... (GH) replacement therapy dosed to normalize IGF-I levels may be ... weight loss program for obese adults. ,The goal of ... retain lean body mass such as muscle,but what happens is ... they stop losing weight. Low levels of GH, known to ...
... rays -- two of which can cause severe skin ... Services at the University of California, the most dangerous ... shorter wavelengths and are primarily responsible for sunburn. Repeated ... immune system and can lead to melanoma and basal ...
... care what the compound microscope was to the biology ... worn on the body, such as a band around ... includes time spent lying down or sleeping, time spent ... ,Few medical advances in recent decades have had ...
... on Friday it expected to announce the removal of the island ... countries where new cases of the deadly virus had been reported ... the disease is 10 days, and twice that time is the ... situation over. ,The move, due to be announced at a ...
Cached Medicine News:Health News:Stem cells offer hope for muscular dystrophy 2Health News:Low-dose Growth Hormone (GH) with diet and exercise may help weight loss 2Health News:SARS-Free Taiwan to Mark End Phase of Global Fight 2
... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
... The Scantibodies Calcitonin Immunoassay is a two-site ... calcitonin. Two different goat polyclonal antibodies to ... chromatography to be specific for well-defined regions ... quantitative determination of Calcitonin in human serum. ...
Calcitonin RIA Kit...
... IMAGE1 is the first completely digital camera ... in the field of endoscopic camera systems. ... the first time, facilitates the fully digital ... quality using an A/D converter, as well ...
Medicine Products: